Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AL-3862+timolol · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| AL-3862+timolol, then COSOPT | OTHER | AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later. |
| COSOPT, then AL-3862+timolol | OTHER | Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later. |
| Name | Type | Description |
|---|---|---|
| AL-3862+timolol ophthalmic suspension | DRUG | - |
| Dorzolamide+timolol ophthalmic solution | DRUG | - |
Inclusion Criteria: * Sign informed consent; * Diagnosis of glaucoma or ocular hypertension; * On a stable regimen of any intraocular pressure (IOP) lowering medication (mono-therapy); * IOP for which, in the opinion of the investigator, participation in the study does not present a risk to ocular ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
AL-3862+timolol is an investigational fixed-dose combination being developed for the treatment of glaucoma and ocular hypertension. It is a small molecule therapy administered in the ophthalmology setting. The drug is currently in Phase 3 clinical development, though the specific trial listed has been completed.
AL-3862+timolol is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is a global medical device and pharmaceutical company focused on eye care, and this combination therapy is part of its ophthalmology pipeline.
AL-3862+timolol is in Phase 3 clinical development. The drug has completed one Phase 3 trial, which was a randomized, double-blind, controlled study. It remains an investigational agent and has not been approved by regulatory authorities for commercial use.
AL-3862+timolol has one completed clinical trial registered under NCT00576342. This Phase 3 study, titled "Patient Preference Study," enrolled 129 participants with glaucoma or ocular hypertension. The trial was randomized, double-blind, and controlled, with participants aged 18 years and older.
AL-3862+timolol is a fixed-dose combination product that contains two active ingredients: AL-3862 and timolol. This combination is being studied as a single therapy for glaucoma and ocular hypertension. The drug is distinct from the individual components and is designed to be administered as one formulation.